At ₹429–430 levels (near 52-week low), Indegene offers excellent risk-reward for 12–24 month horizon. Explosive long-term growth (35% sales CAGR, 68% profit CAGR), first $100M quarter, near-zero debt, and powerful AI/GenAI positioning in the high-growth life-sciences sector make this a high-quality compounder. The sharp correction plus acquisition-related PAT dip has created an attractive entry at just 23.5x PE. Strategy:
- Accumulate on dips below ₹440 (or ₹410–420 zone) for growth portfolios.
- Monitor Q4 FY26 results (late April/early May 2026) and new deal announcements.
- Target: ₹580–650+ in 12–18 months (35–50%+ upside base case).Management commentary (post-Q3 call): Strong momentum in FY26 and beyond.
- FY27 guidance: High-teens to 20%+ revenue growth expected on AI/GenAI ramp-up
- Key levers:
- GenAI solutions adoption by top 20 global biopharma
- Recent acquisitions scaling quickly
- Large deal pipeline in US & Europe
- Structural shift to outcome-based, fixed-price contracts
Have other thoughts on Indegene?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
The user max_profit has a position in NSEI:INDGN. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
